Table 3 Univariate and multivariate survival analysis in all patients.

From: Prognostic relevance of TROP2 expression in patients with non-small cell lung cancer receiving immunotherapy

Different variables

Progression-free survival

Overall survival

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

MST (days)

p-value

HR

95% CI

p-value

MST (days)

p-value

HR

95% CI

p-value

Age

 < 75/ ≥ 75 yrs

189/270

0.430

   

655/443

0.434

   

Sex

Male/Female

232/142

0.888

   

571/395

0.778

   

ECOG PS

0–1 /2–3

270/92

0.001

0.920

0.49–1.73

0.796

784/142

 < 0.001

1.377

0.68–2.75

0.368

Smoking (BI)

Yes/ ≥ No

170/221

0.842

   

611/395

0.658

   

Histology

AC/Non-AC

250/197

0.234

   

611/523

0.283

   

Liver meta

Yes/No

105/251

0.019

2.084

1.10–3.96

0.025

129/714

 < 0.001

2.78

1.34–5.40

0.007

Brain meta

Yes/No

232/202

0.919

   

655/554

0.468

   

Bone meta

Yes/No

105/252

0.020

1.787

1.09–2.94

0.023

272/655

0.011

1.92

1.08–3.33

0.027

NLR

High/Low

134/271

0.010

0.427

0.15–1.18

0.100

334/NR

0.004

0.12

0.04–0.42

0.002

PD-L1 (%)

 ≥ 1/ < 1

205/210

0.611

   

571/443

0.334

   

Ki-67

High/Low

189/208

0.401

   

611/523

0.834

   

TROP2 (Int. × Prop.)

 = 12/ < 12

141/273

0.017

2.034

1.27–3.24

0.003

273/784

0.003

2.82

1.59–5.06

 < 0.001

PLR

High/Low

138/318

0.001

1.164

0.60–2.26

0.652

283/NR

 < 0.001

1.20

0.52–2.51

0.777

SII

High/Low

125/336

 < 0.001

3.896

1.56–9.74

0.004

269/NR

 < 0.001

5.62

1.87–16.2

0.002

PNI

High/Low

318/126

 < 0.001

0.580

0.31–1.08

0.084

NR/233

 < 0.001

0.33

0.15–0.73

0.007

ALI

High/Low

318/129

0.002

1.093

0.38–3.13

0.868

NR/262

 < 0.001

0.47

0.15–1.69

0.237

GPS

High/Low

200/240

0.466

   

571/554

0.674

   
  1. yrs, years; MST, median survival time (days); ECOG PS, eastern cooperative oncology group performance status; BI, brinkman index; AC, adenocarcinoma; non-AC, non-adenocarcinoma; PD-L1, programmed death ligand-1; BI, brinkman index; lymph, lymph node; HR, hazard ratio; 95% CI, 95% confidence interval; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; SII, systemic immune inflammation index; PNI, prognostic nutrition index; ALI, advanced lung cancer inflammation index; GPS, Glasgow prognostic score; PFS, progression-free survival; OS, overall survival; NR, not reached; bold type, statistically significance; int., intensity; prop., proportion; TROP2, Trophoblast surface antigen 2.
Back to article page